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might result in new innovations for perinatal 
psychiatric therapies. Furthermore, perinatal psychiatric 
intervention studies are crucial to provide evidence-
based guidelines on effective treatment of perinatal 
mental disorders for clinicians. Clear guidelines are 
needed to be able to support new parents and their 
babies more efficiently, especially in these times of the 
coronavirus disease 2019 pandemic, filled with anxiety 
and worries.
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Evidence for preventive treatments in young patients at 
clinical high risk of psychosis: the need for context
Cochrane reviews, as rigorous evaluations of evidence 
in health care, have a substantial effect on clinical and 
policy decision-making; however, their findings and 
methods need to be contextualised. These reviews are 
done by groups of academics who might or might not 
have adequate expertise or clinical experience in the 
field they examine, and we feel the methods can be 
indeterminate and conservative.
The recent Cochrane review1 of intervention trials for 
patients at clinical high risk of psychosis concluded that, 
despite the considerable research effort in this area, the 
evidence base was weak and firm conclusions could not 
yet be drawn. The authors noted that the “strongest 
weak evidence” supported the ability of omega-3 fatty 
acids to prevent the onset of psychosis in the clinical high 
risk population, but that the quality of evidence overall 
was low to very low.
We have several methodological concerns about the 
Cochrane review.1 First, a major contributor to the low-
to-very-low quality rating of studies was their risk of 
bias (eg, randomisation and allocation concealment 
methods not being described, the risk of unblinding, 
and high attrition). However, many studies included in 
the review used rigorous methods of randomisation and 
allocation concealment without detailing these in print.2 
Moreover, most mentioned studies were psychosocial 
or psychotherapy trials, in which it is impossible to 
implement masking of therapists and notoriously 
difficult to maintain patient masking. High attrition is 
also common in all trials involving youth with mental 
disorders.
Second, derived from studies of medications for 
acutely unwell patients with psychosis, the criterion 
of a 50% reduction in symptoms used to judge clinical 
improvement might be inappropriate for the clinical high 
risk group and represents an unrealistic goal for a group of 
patients who, by definition, have symptoms of moderate 
intensity.3 Even in clinical trials of pharmacological and 
psychological interventions for acutely ill patients with 
first-episode psychosis and schizophrenia, response is 
usually set between 20% and 50% symptom reduction.4
Finally, the Cochrane review compared different 
categories of interventions across randomised controlled 
trials (RCTs) with control conditions.1 Although this 
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method is arguably a better approach than network 
meta-analyses, it meant that the critical issue of 
whether, when all pooled together, specific targeted 
interventions were superior to standard treatment was 
left unaddressed. When this issue has been addressed, 
the onset of psychosis in the clinical high risk population 
could at least be delayed through specific targeted 
treatments, with a 50% risk reduction over 12 months.5,6
The Cochrane review did show the benefits of 
cognitive behavioural therapy (CBT) over supportive 
therapy, with a number needed to treat (NNT) of 13 
over 1 year and a relative risk of 0·45 (about 8% vs 16% 
transition rate), however, the conclusion and summary 
sections downplayed this important finding.1 An NNT 
of 13 is certainly clinically meaningful and compares 
favourably with antipsychotic medication preventing 
psychosis relapse, as well as treatments in other areas 
of medicine.7,8 The decline in the effect of CBT over time 
is not unique, with treatments needing to be sustained 
in many other health conditions (eg, antipsychotic 
medication for psychosis relapse prevention and insulin 
for diabetes).
The Cochrane review ignored biological analysis 
from the RCTs that supported the protective function 
of omega-3 fatty acids.1 These studies indicated that 
omega-3 concentrations at baseline and their increase 
in clinical high risk trial participants predict clinical 
improvement, highlighting the potential value of 
omega-3 fatty acids as a treatment option.9
The authors correctly pointed out that treatment 
studies have consistently been underpowered. Although 
prioritising multisite studies to increase sample size is 
certainly one solution, the Cochrane review1 ignored 
the importance of enriching samples in order to 
evaluate preventive treatments. Stratification of risk 
within clinical high risk cohorts is a highly active area of 
research.
Standard treatment is not a fixed entity. Background 
service-level contextual factors are likely to have 
improved over time and standard treatment to have 
been refined. Therefore, the control and comparison 
conditions have probably become more effective in 
recent trials, which, coupled with the observed rise in 
placebo response, means that trial interventions need to 
improve on already efficacious treatments.
The authors recommended a two-stage approach 
for future treatment studies, which firstly compares 
low-dose, antipsychotic medication with psychosocial 
treatment as usual before progressing to a second step 
that compares different components of the psychosocial 
treatment as usual. The recommendation to use 
antipsychotic medications first is incongruent with the 
evidence base, as outlined in the Cochrane review itself, 
with an unfavourable risk–benefit ratio.1
The evidence base needs to be regularly reviewed; 
however, the details of the methodological approach 
taken and the broader context of the treatment trials 
are both essential. Although we agree that more high-
quality research trials are needed to enhance outcomes 
and determine the most effective type and sequence 
of interventions, the evidence base shows that help-
seeking individuals at clinical high risk benefit from the 
available treatments, including standard treatment, 
without iatrogenic harm associated with antipsychotic 
medications.10 This potential for improvement is a key 
message for patients, families, and practitioners. We 
are concerned that this recent Cochrane review instead 
negatively framed the evidence base and did not convey 
any treatment benefits.1 If heeded, the review’s message 
would result in many help-seeking young people being 
denied much needed psychosocial care and being exposed 
to the risks of worsening symptoms and functioning.
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Ethnicity and mental health: a new beginning
The UK is a high-income country with a publicly funded 
mental health-care system, which is free at the point 
of use. The UK’s National Health Service (NHS), like 
other public bodies, is legally obliged to ensure fair and 
equal services. However, ethnic inequalities remain 
established in most aspects of mental health care in the 
UK.1 Black and minority ethnic (BME) people do not do 
as well as the white majority in any aspect of mental 
health care and, generally, they fare much worse.
The nature and extent of racial discrimination 
in  mental health care has been known for over half 
a century. Over the years, however, there has been 
no change in the experiences of people from BME 
communities who use mental health services. Despite 
the continuing rhetoric on race and mental health,2,3 and 
more promises of change,4 there is no parity between 
BME communities and the white majority in access, 
experience, or outcomes of mental health care.5
There are several reasons for this absence of 
progress in reducing ethnic inequalities in mental 
health care. First, most academic and professional 
focus in this area has been on the probable reasons 
for the ethnically differentiated nature of psychiatric 
care, rather than on the shortcomings within current 
services. Second, changing established practices 
creates a sense of helplessness and pessimism. Third, 
despite various policy initiatives on race and mental 
health, there is still no national plan or strategy to 
reduce race inequalities in treatment and outcomes. 
Fourth, political and professional leadership has largely 
been absent in both the government and the NHS in 
tackling ethnic inequalities. The lack of commitment is 
evident from the continuing failure to implement the 
recommendations from various reviews and national 
inquiries, and omission of any investment in this area.
Further inquiries or reviews will add little to what 
is already known. The problems are already well 
understood, and despite the complexity of underlying 
issues, it is clear what changes are required. For 
example, a wealth of evidence exists that is based on the 
experience of service users and the black communities, 
and many examples of what works for the benefit of 
patients and their families (panel). Most crucially, the 
BME communities and agencies are engaged and willing 
to work with statutory providers to bring about change.
The Ethnicity and Mental Health Improvement Project 
(EMHIP) in Wandsworth, southwest London, UK, is 
an attempt to bridge the gap between policy rhetoric 
and practice. EMHIP is a collaborative project involving 
the local mental health service, South West London 
and St George’s Mental Health NHS Trust (SWLSTG), 
and a BME community mental health organisation, 
Wandsworth Community Empowerment Network 
(WCEN). WCEN has been at the forefront of challenging 
the unjust patters of mental health care in southwest 
London as well as mobilising resources and creating 
networks in the local community.6 Although SWLSTG 
and WCEN have worked together for over a decade, they 
have been unable to change the ethnically differentiated 
pattern of mental health care locally. Over the years, 
it has become clear that fundamental reconfiguration 
Panel: Evidence for changing ethnic disparities in mental 
health care
• Evidence based on research, national inquiries, and reports
• Evidence based on experience: service users and black 
and minority ethnic communities
• Examples of good practice
• Local evidence from services and communities
